In yet another setback to the treatment of Alzheimer’s disease, Axovant Sciences has announced that their latest attempt at creating a treatment - a drug known as Intepirdine (a (5-HT)6 receptor antagonist) - has failed during late stage clinical trials. Meanwhile, pharmaceutical giant Pfizer Inc has announced plans to leave the field of … [Read more...] about Axovant fails while Pfizer leaves – the grim outlook of Alzheimer’s research
Archives for February 2018
A robotic takeover has long been thought of as the stuff of nightmares, from being a staple of science fiction doomsday scenarios to being warned of by sci-tech leaders such as Elon Musk as an outcome if artificial intelligence (AI) technology continues to grow. In contrast to these bleak predictions on the future of robotics, however, the … [Read more...] about Robotic takeover of healthcare on the horizon?
Alzheimer’s research may see a well needed boost in the form of a research deal funded by Chicago based pharmaceutical group AbbVie. The recipient research group, Alector, is to receive a $205 million USD up front payment, as well as future equity investments worth up to $20 million. Alector has seen a great deal of interest within the … [Read more...] about Immunotherapy: the future of Alzheimer’s research?
Children in Africa have shown a prevalence of up to 54 percent of HIV strains which display a resistance to one or more commonly used antiretroviral (ARV) drugs according to a study published in Clinical Infectious Diseases. Is this an indication that currently used medications may prove to be ineffective in years to come? Africa has seen a … [Read more...] about Drug resistant HIV and the potential to render current treatments inviable